Cargando…
Preliminary evaluation of prostate‐targeted radiotherapy using (131)I‐MIP‐1095 in combination with radiosensitising chemotherapeutic drugs
OBJECTIVES: Despite recent advances in the treatment of metastatic prostate cancer, survival rates are low and treatment options are limited to chemotherapy and hormonal therapy. (131)I‐MIP‐1095 is a recently developed prostate‐specific membrane antigen (PSMA)‐targeting, small molecular weight radio...
Autores principales: | Tesson, Mathias, Rae, Colin, Nixon, Colin, Babich, John W., Mairs, Robert J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298040/ https://www.ncbi.nlm.nih.gov/pubmed/27139157 http://dx.doi.org/10.1111/jphp.12558 |
Ejemplares similares
-
Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with (131)I-MIP-1095
por: Afshar-Oromieh, Ali, et al.
Publicado: (2017) -
Cell cycle specific radiosensitisation by the disulfiram and copper complex
por: Tesson, Mathias, et al.
Publicado: (2017) -
Radiation dosimetry and first therapy results with a (124)I/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
por: Zechmann, Christian M., et al.
Publicado: (2014) -
Radiosensitization of noradrenaline transporter-expressing tumour cells by proteasome inhibitors and the role of reactive oxygen species
por: Rae, Colin, et al.
Publicado: (2013) -
An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
por: Nile, Donna L., et al.
Publicado: (2016)